This site uses cookies to ensure the best viewing experience for our readers.
Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering

Brief

Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering

The Israel-based cancer immunotherapy company intends to use the proceedings for product development

Dror Reich | 12:26  17.06.2018

Israel-based cancer immunotherapy company Compugen Ltd. was down 3.75% on Nasdaq on Friday market close after announcing a $21 million registered direct offering of ordinary shares and warrants, at $3.95 per share. The offering is expected to close on Tuesday. Clinical-stage Compugen intends to use the funding for product development. In April, Compugen announced an exclusive license agreement with Anglo-Swedish pharmaceutical company AstraZeneca PLC.

Nasdaq. Photo: Getty Images Nasdaq. Photo: Getty Images Nasdaq. Photo: Getty Images

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS